Sugammadex vs Placebo to Prevent Residual Neuromuscular Block
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The study is designed to determine whether patients who receive sugammadex immediately after
tracheal extubation will exhibit a decrease in the incidence of postoperative residual
paralysis and an associated decrease in the incidence of postoperative respiratory
depression.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Merck Sharp & Dohme Corp. Respiratory Motion, Inc. University of Texas University of Texas, UTHealth